Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
T

ASCO® GU 2024 Insights: "OS Results From the KEYNOTE-564 Study - Adjuvant Pembro vs. Placebo for the Treatment of ccRCC"

By Dana-Farber Cancer Institute FEATURING Toni Choueiri
By Dana-Farber Cancer Institute FEATURING Toni Choueiri
53 views
February 20, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
ASCO® GU 2024
22:03
Dana-Farber Cancer Institute

RCC Highlights From ASCO® GU 2024

Feat. W. Xu, T. Choueiri
02:31
Dana-Farber Cancer Institute

Testicular Cancer Highlights From ASCO® GU 2024

Feat. A. Tewari
22:58
Dana-Farber Cancer Institute

Bladder Cancer Highlights From ASCO® GU 2024

Feat. C. Mantia, J. Bellmunt
23:03
Dana-Farber Cancer Institute

Prostate Cancer Highlights From ASCO® GU 2024

Feat. J. Berchuck, A. Choudhury
02:23
Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Association of DAZL Expression With Ri…

Feat. A. Tewari
02:31
Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Rate of Hospitalization and Length of …

Feat. A. Morgans
02:35
Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "OS Results From the KEYNOTE-564 Study …

Feat. T. Choueiri
02:38
Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Impact of Race on Outcomes to 177Lu-PS…

Feat. A. Rami
02:22
Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Patient Characteristics, Treatment Pat…

Feat. X. Wei